All News
In the ESPOIR cohort of 813 RA followed for 10 years, polypharmacy associated w/ less DAS28 ESR Remission at 5 (45.0% in vs. 56.3% (p=0.03)) and 10 yrs (32.5% vs. 67.5% (p=0.06)) BUT no longer significant when adjusted for comorbidities!
#EULAR2021 @Rheumnow #OP0098 https://t.co/pSrr1dzKFP
Aurelie Najm AurelieRheumo ( View Tweet)
Double hit”: #OP0015
Phase IIA ABBV-3373 (Adalimumab linked to GC receptor modulator GRM) vs. PBO and historic ADA show promising results with a satisfactory safety profile compared to ADA. A potential new IV drug in RA! #EULAR2021 @Rheumnow https://t.co/mqLtXx9zBI
Aurelie Najm AurelieRheumo ( View Tweet)
Acute Coronary Syndrom incidence in > 24,000 RA from Nordic registers followed up to 5 yrs = 5.5/1000 pyrs. After 5yrs RTX show > risk of ACS compared to ETA. In patient with >= 2 previous DMARDs ABA, INF and RTX > risk of ACS compared to ETA.
#EULAR2021 @Rheumnow #OP0114 https://t.co/MjW9LI2cjt
Aurelie Najm AurelieRheumo ( View Tweet)
Patients with RA > 70yo and risk of severe infection: which therapeutic strategy is the safest?
#EULAR2021 @Rheumnow #OP0116
Aurelie Najm AurelieRheumo ( View Tweet)
Dr Yoshida analyze data from US registry 40,721 RA patients. High 2.11 [1.13, 3.96] and moderate 1.97 [1.13, 3.43] CDAI associated w/ > HR of major adverse CV events. HRs decrease during follow up.
Tight and early disease control reduces CV burden!
#EULAR2021 @Rheumnow #OP0101 https://t.co/A0ZYE4v8uf
Aurelie Najm AurelieRheumo ( View Tweet)
In 16,448 RA from ACR’s RISE registry: no difference in disease activity TNFi and non-TNFi at 12 months. Stratified analysis: ⬆️disease activity for TNFi vs. non TNFi in patients of Black and Asian ethnicity. To be confirmed in independent cohorts.
#EULAR2021 @Rheumnow #OP0117 https://t.co/7bFnOKR9uz
Aurelie Najm AurelieRheumo ( View Tweet)
MTX or ETA which one withdraw first? @RADoctor SEAM-RA trial: PROs following withdrawal of MTX or ETN in RA patients with sustained SDAI remission receiving combination ETN+MTX. ETA > MTX for maintaining SDAI remission at W48 (49.5%-28.7% P=0.004)
#EULAR2021 @Rheumnow #OP0118 https://t.co/MSOclXGMEK
Aurelie Najm AurelieRheumo ( View Tweet)
Rheum alliance trainee survey (n=302):
87-96% report negative impact of COVID19 on Rheumatology training:
-outpatient clinics (79%)
-inpatient consultations (59%)
-formal teaching (55%)
-procedures (53%) and
-ultrasonography (36%)
#POS0051 @RheumNow #EULAR2021 @kristenyoung
Aurelie Najm AurelieRheumo ( View Tweet)
Can we predict pre-clinical RA-ILD?
@Juge_P_A ESPOIR cohort. model w/ 4 variables: male gender, older age @ diag, mean DAS-28 over follow-up and MUC5B variant ▶️ preclinical ILD after 13 years of RA w/ AUC=0.82 CI 95% (0.72-0.91) (Sens 80%, Spe 56%)
#POS0095 @Rheumnow #EULAR2021 https://t.co/bPyidNhNuO
Aurelie Najm AurelieRheumo ( View Tweet)
Curious to find out the answer?https://t.co/cXjUeQAwHD
#EULAR2021 @RheumNow #OP0012 https://t.co/7q5yZLD96v
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Very informative #EULAR2021 WIN session on MIS-C @EULAR_org
👉 Steroids early
👉 IVIg in all
👉 anticoagulant use remains variable
#Coronary aneurysms
✅ occur during acute phase in MIS-C and improve with treatment
✅ occur in the late/convalescent phase of #Kawasaki disease https://t.co/Ff3rX6u5VK
Ashima Makol MD AshimaMakol ( View Tweet)
Does skin #lupus respond differently to rituximab?Dr Carter @LucyCarter6 reported 75% cutaneous response rate but overall non-response to tx was caused by skin domain. Interestingly, resistant skin post-tx was associated with low baseline #IFN scores #EULAR2021 #OP0134 @RheumNow https://t.co/JdtwdwNR4Z
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Can machine learning show JAKi effects for safety? Off target binding predicted in #tofacitinib 58, #baricitinib 41 but NO pathway for thrombosis or viral infection. Could have repurposing for + effects on lung vasculature & antifibrotic effects POS0091 #EULAR2021 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
MACE events with #JAKi is as clear as mud! You voted >50% NOT Sure 1/3 only some Jakis vs MACE in #TNFi! Dunno #EULAR2021 @RheumNow @eular_org https://t.co/vWUgKSwAap
Janet Pope Janetbirdope ( View Tweet)
Does anti-CD20 mAb still have a place in #Sjogren? Dr Pontarini analysed salivary gland biopsy from TRACTISS and reported beneficial effects of RTX in⬇️regulating genes involved in immune cell recruitment, activation and organisation in ectopic GC #EULAR2021 #OP0136 @RheumNow https://t.co/FRUvo4JxTx
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Do you increase spacing of TNF-i administration in your patients with axSpA with sustained low disease activity for one year? OP0138 results showed similar relapse rates in those with increased spacing intervals and those on standard dosing regimen. #EULAR2021 @RheumNowNews
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Does Guselkumab (IL23-i) modulate gene expression in #PsA? Dr Siebert analysed samples from DISCOVER RCTs & reported normalisation of⬆️regulated genes (e.g. Neutrophil,monocyte) and ⬇️regulated (B-,T- and NK cells) signatures by GUS post-therapy #EULAR2021 #POS0195 @RheumNow https://t.co/2qtpxrrwkF
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
AVN in SLE is ⬇️ing over time! risks are same: younger, male, glucocorticoids & also found hyperlipidemia. ?due to older age of onset & less steroids over time & better immune suppressants POS0730 @RheumNow #EULAR2021 @eular_org https://t.co/IG3NVrZl4D
Janet Pope Janetbirdope ( View Tweet)
Once approved, what type of patients with #SLE would you treat with #anifrolumab? #EULAR2021 #OP0131 @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Sjogren’s QoL reported dryness correlates with objective salivary flow
⭐️lower perceived dryness associated with higher immunologic activity
Abs#POS0102
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)